Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-12 pm EDT 5-day change 1st Jan Change
41.85 USD -0.38% Intraday chart for Cerevel Therapeutics Holdings, Inc. -0.76% -1.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing MT
Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sector Update: Health Care Stocks Gain Late Afternoon MT
AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions MT
Phew! The party continues! Our Logo
AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports RE
North American Morning Briefing : Stock Futures -2- DJ
AbbVie CEO to Retire; COO Robert Michael Named Successor MT
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating MT
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase AN
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance MT
AbbVie 4Q Sales Lower as Himura Revenue Sinks DJ
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals RE
Neumora Therapeutics Names Kaya Pai Panandiker as Chief Commercial Officer MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $424,700, According to a Recent SEC Filing MT
JPMorgan Raises Price Target on Cerevel Therapeutics Holdings to $45 From $25, Keeps Neutral Rating MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $331,608, According to a Recent SEC Filing MT
Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40 MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $571,972, According to a Recent SEC Filing MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $259,144, According to a Recent SEC Filing MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $292,945, According to a Recent SEC Filing MT
Cerevel Therapeutics Holdings Insider Sold Shares Worth $326,788, According to a Recent SEC Filing MT
Trending : Bristol Myers to Buy Karuna Therapeutics for $14 Billion DJ
Cerevel Therapeutics Holdings Insider Sold Shares Worth $413,700, According to a Recent SEC Filing MT
Chart Cerevel Therapeutics Holdings, Inc.
More charts
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
41.85 USD
Average target price
44.78 USD
Spread / Average Target
+7.00%
Consensus
  1. Stock Market
  2. Equities
  3. CERE Stock
  4. News Cerevel Therapeutics Holdings, Inc.
  5. Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40